219A.T
Heartseed Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 2,172.00
−2.29%Income statement
| Metric | TTM | 2025 | 2024 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | 3.0B | 3.0B | 873.0M |
| Cost of Revenue | — | — | — |
| Gross Profit | 2.4B | 3.0B | 873.6M |
| Operating Expenses | |||
| R&D Expense | — | — | — |
| SG&A Expense | 1.6B | 2.8B | 1.9B |
| General & Admin Expense | — | — | — |
| Selling & Marketing Expense | — | — | — |
| Other Expenses | — | — | — |
| Total Operating Expenses | 1.6B | 2.8B | 1.9B |
| Cost and Expenses | 2.3B | 2.8B | 1.9B |
| Operating Income (EBIT) | 682.0M | 272.0M | (1.0B) |
| Non-Operating | |||
| Interest Income | 6.4M | 5.9M | 401.0K |
| Interest Expense | 79.0K | 159.0K | 409.0K |
| Net Interest Income | 1.6M | 5.8M | (8.0K) |
| Other Non-Op Income/Expense | (53.4M) | 16.8M | 220.2M |
| Non-Operating Income (excl Interest) | 7.2M | 52.6M | 261.7M |
| EBT (Pre-Tax Income) | 726.5M | 289.0M | (818.6M) |
| Income Tax Expense | 62.5M | 98.4M | (5.9M) |
| Bottom Line | |||
| Net Income | 610.0M | 190.0M | (812.0M) |
| Earnings from Cont. Ops | — | — | — |
| Earnings from Discont. Ops | — | — | — |
| Bottom Line Net Income | 610.0M | 190.0M | (812.0M) |
| Per Share | |||
| Basic EPS | ¥27 | ¥8 | (¥49) |
| Diluted EPS | ¥27 | ¥8 | — |
| Revenue Per Share | ¥131 | ¥134 | ¥53 |
| Shares | |||
| Basic Shares Outstanding | 22.9M | 22.6M | 16.4M |
| Diluted Shares Outstanding | — | — | — |
| Profitability Metrics | |||
| EBITDA | — | 325.0M | (996.2M) |
| D&A | — | 53.0M | 41.8M |
| EBIT | 682.0M | 272.0M | (1.0B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026